Showing results (131-140 of 178) with videos related to
Sort By:
Pageof 18
Cancer|July 23, 2026
Vobramitamab duocarmazine, an anti-B7-H3 antibody-drug conjugate, in patients with advanced solid tumors: Final results of a phase 1 cohort expansionEugene Shenderov, Manish R Sharma, Elena Garralda, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 23, 2026
Datopotamab Deruxtecan Plus Pembrolizumab With or Without Platinum-Based Chemotherapy for Advanced or Metastatic NSCLC: The Phase Ib TROPION-Lung02 TrialBenjamin Levy, Luis Paz-Ares, Chien-Chung Lin, et al.Applied and Environmental Microbiology|April 3, 2026
Mycorrhizal competition release and microbial dynamics in native and non-native Tuber melanosporum habitatsGian Maria Niccolò Benucci, Sergi Garcia-Barreda, Sergio Sanchez, et al.Cancer Chemotherapy and Pharmacology|March 17, 2022
First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancersEnriqueta Felip, Victor Moreno, Daniel Morgensztern, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 6, 2019
Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 TrialR Wendel Naumann, Antoine Hollebecque, Tim Meyer, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 30, 2021
Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 AntibodyJames J Harding, Victor Moreno, Yung-Jue Bang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 4, 2011
A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumorsFrancesco Atzori, Josep Tabernero, Andrés Cervantes, et al.Journal for Immunotherapy of Cancer|November 20, 2024
Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1)Ulka N Vaishampayan, Jameel Muzaffar, Ira Winer, et al.Clinical and Translational Science|May 23, 2026
Safety and Efficacy of HexaBody-DR5/DR5 in Malignant Solid Tumors: Phase 1/2a Results and Translational Insights Into Observed HepatotoxicityMarije B Overdijk, Kristin Strumane, Ruth Plummer, et al.Journal of Alzheimer'S Disease : JAD|May 21, 2025
Performance of a smell identification test versus the Mini-Mental Status Exam for the detection of dementia and cognitive impairment among persons with cognitive concerns in primary careJosé A Luchsinger, Jeanne A Teresi, Lenfis Valdez, et al.Pageof 18